Atea Pharmaceuticals, Inc. (AVIR)
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Atea Pharmaceuticals, Inc.
NASDAQ:AVIRHealthcare · Biotechnology
-4.64%$4.11
AH$4.11+0.00%vs close
Mkt Cap$329.64M
Float61.12M
O/S80.2M
Vol
$ Vol
RVOL
Inst Own74.2%
SI5.0%
Earnings
Dilution
Financials Summary
Revenue$0
Net Income-$158.35M
Total Assets$315.22M
Free Cash Flow-$132.03M
Debt & Equity
Debt 0%
Equity 100%
Total Debt$843K
Total Equity$275.43M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:11Reverse splitFeb 14, 201811 shares → 1
Balance Sheet Details
Assets$315.22M
Liabilities$39.78M
Accounts Receivable$0
Accounts Payable$12.95M
Inventory$0
PP&E (Net)$1.09M
Goodwill$0
Intangible Assets$0
Income Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $0 | $0 | $0 | $0 | $351.37M | $48.63M | $0 | $0 |
| YoY Growth | - | - | - | - | 622.5% | - | - | - |
| Cost of Revenue | $0 | $83.37M | $70.09M | $62.39M | $167.21M | $38.02M | $17K | $17K |
| Gross Profit | $0 | -$83.37M | -$70.09M | -$62.39M | $184.16M | $10.61M | -$17K | -$17K |
| Gross Margin | - | - | - | - | 52.4% | 21.8% | - | - |
| Research and Development | $148.02M | $145.4M | $132.84M | $88.84M | $167.21M | $38.02M | $10.17M | $6.67M |
| Selling, General, and Administrative | $32.86M | $48.85M | $49.92M | $48.71M | $45.78M | $21.64M | $4.44M | $2.8M |
| Other | $0 | -$84.67M | -$88.69M | -$69.29M | -$167.21M | -$38.02M | $0 | $0 |
| Total Operating Expenses | $180.89M | $109.58M | $94.07M | $68.26M | $45.78M | $21.64M | $14.61M | $9.48M |
| Operating Income (EBIT) | -$180.89M | -$192.95M | -$164.16M | -$130.65M | $138.38M | -$11.03M | -$14.61M | -$9.48M |
| Operating Margin | - | - | - | - | 39.4% | -22.7% | - | - |
| Interest Expense | $0 | $0 | $0 | $11.15M | $0 | $0 | $0 | $0 |
| Interest Income | $16.38M | $25.49M | $29.22M | $11.15M | $213K | $83K | $574K | $413K |
| Other Income (Expense) | $16.38M | $25.49M | $29.22M | $11.15M | $213K | $83K | $574K | $413K |
| Income Before Tax (EBT) | -$164.51M | -$167.46M | -$134.94M | -$119.5M | $138.59M | -$10.95M | -$14.03M | -$9.06M |
| Income Tax Expense | -$6.16M | $925K | $1.02M | -$3.59M | $17.4M | $0 | $0 | $0 |
| Net Income | -$158.35M | -$168.38M | -$135.96M | -$115.91M | $121.19M | -$10.95M | -$13.46M | -$9.06M |
| Net Income Margin | - | - | - | - | 34.5% | -22.5% | - | - |
| Supplementary Data | ||||||||
| EPS | -1.94 | -2.00 | -1.63 | -1.39 | 1.46 | -0.13 | -0.16 | -0.90 |
| Diluted EPS | -1.94 | -2.00 | -1.63 | -1.39 | 1.37 | -0.13 | -0.16 | -0.90 |
| Weighted Average OS | 81.50M | 84.26M | 83.39M | 83.25M | 82.82M | 82.44M | 82.62M | 10.09M |
| EBITDA | -$164.09M | -$131.8M | -$119.59M | -$110.84M | $138.62M | -$11.01M | -$14.59M | -$9.46M |
| EBITDA Margin | - | - | - | - | 39.5% | -22.6% | - | - |
Balance Sheet
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $95.71M | $64.7M | $143.82M | $646.71M | $764.38M | $850.12M | $21.66M | $34.49M |
| Short-Term Investments | $206.12M | $390.02M | $434.28M | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $301.83M | $454.72M | $578.11M | $646.71M | $764.38M | $850.12M | $21.66M | $34.49M |
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | $5.82M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $9.16M | $7.63M | $12.35M | $14.21M | -$0 | $0 | $249K | $0 |
| Total Current Assets | $310.99M | $462.36M | $590.46M | $660.92M | $772.4M | $863.48M | $21.91M | $34.7M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $1.09M | $2.12M | $3.12M | $4.09M | $184K | $48K | $41K | $56K |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $198K | $305K | $107K | $107K | $107K |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.14M | $197K | $1.4M | $1.49M | $0 | $0 | $15K | $0 |
| Total Long-Term Assets | $4.23M | $2.31M | $4.51M | $5.79M | $489K | $155K | $163K | $163K |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $315.22M | $464.67M | $594.97M | $666.71M | $772.89M | $863.63M | $22.07M | $34.86M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $12.95M | $4.46M | $4.25M | $2.55M | $4.53M | $60K | $548K | $391K |
| Short-Term Debt | $843K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $0 | $0 | $99K | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $301.37M | $200K | $200K |
| Other Current Liabilities | $19.56M | $7.44M | $0 | $8.65M | $27.57M | $11.63M | $1.69M | $200K |
| Total Current Liabilities | $39.78M | $18.6M | $32.38M | $18.48M | $56.88M | $315.8M | $2.44M | $1.76M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $6.36M | $5.76M | $5.25M | $5.93M | $36K | $95K | $69.26M |
| Total Long-Term Liabilities | $0 | $7.2M | $7.4M | $7.66M | $5.93M | $36K | $95K | $69.26M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $39.78M | $25.8M | $39.78M | $26.14M | $62.81M | $315.83M | $2.53M | $71.02M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $863.63M | $69.11M | $69.11M |
| Common Stock | $78K | $84K | $83K | $83K | $83K | $82K | $10K | $10K |
| Retained Earnings | -$522.57M | -$364.22M | -$195.84M | -$59.88M | $56.03M | -$65.16M | -$54.21M | -$40.18M |
| Comprehensive Income & Other | $174K | $233K | $207K | -$684K | -$0 | -$863.63M | $0 | -$69.11M |
| Other Stockholders' Equity | $797.92M | $803M | $750.94M | $700.37M | $653.96M | $612.88M | $73.75M | $4.01M |
| Total Equity | $275.43M | $438.87M | $555.19M | $640.57M | $710.08M | $547.8M | $19.54M | -$36.16M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $315.22M | $464.67M | $594.97M | $666.71M | $772.89M | $863.63M | $22.07M | $34.86M |
| Supplementary Data | ||||||||
| Total Debt | $843K | $1.64M | $2.4M | $3.12M | $197K | $0 | $0 | $0 |
| Net Debt | -$94.87M | -$63.05M | -$141.42M | -$643.59M | -$764.18M | -$850.12M | -$21.66M | -$34.49M |
Cash Flow Statement
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$158.35M | -$168.38M | -$135.96M | -$115.91M | $121.19M | -$10.95M | -$14.03M | -$9.06M |
| Depreciation & Amortization | $416K | $416K | $416K | $260K | $29K | $19K | $17K | $17K |
| Deferred Income Tax | -$6.36M | $0 | -$48.56M | $0 | -$29.39M | $0 | -$501K | $0 |
| Stock-Based Compensation | $20.72M | $51.77M | $49.43M | $46.72M | $39.62M | $7.46M | $624K | $414K |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | $0 | $0 | $0 | $0 | $0 | -$5.82M | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $8.49M | $206K | $1.7M | -$1.98M | $10.29M | -$488K | $157K | -$90K |
| Other Working Capital | $8M | -$7.68M | $14.46M | -$44.6M | -$258.13M | $306.51M | $422K | $815K |
| Total Working Capital Change | $16.48M | -$7.48M | $16.16M | -$46.59M | -$247.84M | $300.2M | $579K | $725K |
| Other Non-Cash Items | -$4.94M | -$11.82M | $33.11M | -$5.46M | $29.39M | $0 | $501K | $538K |
| Net Cash from Operating | -$132.03M | -$135.5M | -$85.39M | -$120.98M | -$87M | $296.73M | -$12.81M | -$7.91M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $0 | $0 | -$1.94M | -$4K | -$26K | -$2K | -$12K |
| Acquisitions | $0 | $0 | $0 | $453K | $0 | $0 | $0 | $0 |
| Purchases of Investments | -$281.94M | -$461.18M | -$562.36M | -$545.35M | $0 | $0 | $0 | $0 |
| Sales of Investments | $470.73M | $517.28M | $602.66M | $91.89M | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$453K | $0 | $0 | $0 | $0 |
| Net Cash from Investing | $188.79M | $56.1M | $40.3M | -$455.41M | -$4K | -$26K | -$2K | -$12K |
| Financing Activities | ||||||||
| Debt Repaid | - | - | - | - | - | - | - | - |
| Common Stock Issuance | $259K | $267K | $257K | $230K | $1.47M | $317.63M | -$15K | $124K |
| Common Stock Repurchases | -$25.52M | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$485K | $0 | $0 | $140K | $0 | $0 | $0 | $27.48M |
| Net Cash from Financing | -$25.75M | $267K | $257K | $370K | $1.47M | $531.75M | -$15K | $27.48M |
| Forex Effect | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $31.02M | -$79.13M | -$44.84M | -$576.02M | -$85.54M | $828.46M | -$12.83M | $19.56M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$132.03M | -$135.5M | -$85.39M | -$120.98M | -$87M | $296.73M | -$12.81M | -$7.91M |
| Capital Expenditure | $0 | $0 | $0 | -$1.94M | -$4K | -$26K | -$2K | -$12K |
| Free Cash Flow | -$132.03M | -$135.5M | -$85.39M | -$122.92M | -$87.01M | $296.71M | -$12.82M | -$7.92M |
| Cash at Beginning | $64.7M | $143.82M | $188.66M | $764.68M | $850.22M | $21.77M | $34.6M | $15.04M |
| Cash at End | $95.71M | $64.7M | $143.82M | $188.66M | $764.68M | $850.22M | $21.77M | $34.6M |